W.H. Cornerstone Investments Inc. Makes New Investment in Chemed Corporation $CHE

W.H. Cornerstone Investments Inc. acquired a new stake in Chemed Corporation (NYSE:CHE) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 493 shares of the company’s stock, valued at approximately $240,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. SVB Wealth LLC bought a new position in shares of Chemed during the first quarter worth about $30,000. WPG Advisers LLC purchased a new stake in Chemed in the first quarter worth approximately $32,000. Creekmur Asset Management LLC bought a new stake in shares of Chemed in the second quarter worth about $28,000. Parkside Financial Bank & Trust lifted its position in Chemed by 86.3% during the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after acquiring an additional 44 shares during the period. Finally, Geneos Wealth Management Inc. lifted its position in Chemed by 330.4% in the 1st quarter. Geneos Wealth Management Inc. now owns 99 shares of the company’s stock valued at $61,000 after acquiring an additional 76 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Insider Activity at Chemed

In other Chemed news, CEO Kevin J. Mcnamara sold 3,000 shares of the company’s stock in a transaction dated Friday, September 26th. The stock was sold at an average price of $461.28, for a total value of $1,383,840.00. Following the completion of the transaction, the chief executive officer owned 96,197 shares of the company’s stock, valued at $44,373,752.16. This represents a 3.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Patrick P. Grace sold 150 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $463.39, for a total value of $69,508.50. Following the completion of the transaction, the director directly owned 3,397 shares in the company, valued at $1,574,135.83. This represents a 4.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 3.29% of the company’s stock.

Chemed Price Performance

NYSE CHE traded up $2.73 on Thursday, hitting $450.28. 12,615 shares of the company were exchanged, compared to its average volume of 153,046. The company’s 50 day moving average price is $444.87 and its 200-day moving average price is $485.34. The firm has a market capitalization of $6.38 billion, a P/E ratio of 23.81, a price-to-earnings-growth ratio of 2.69 and a beta of 0.43. Chemed Corporation has a twelve month low of $408.42 and a twelve month high of $623.60.

Chemed (NYSE:CHE) last released its quarterly earnings data on Tuesday, October 28th. The company reported $5.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.39 by ($0.12). Chemed had a net margin of 11.02% and a return on equity of 25.89%. The firm had revenue of $624.90 million for the quarter, compared to analyst estimates of $626.04 million. During the same period in the previous year, the business posted $5.64 EPS. Chemed’s revenue for the quarter was up 3.1% on a year-over-year basis. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts expect that Chemed Corporation will post 21.43 EPS for the current year.

Chemed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Monday, November 17th will be paid a $0.60 dividend. The ex-dividend date of this dividend is Monday, November 17th. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. Chemed’s payout ratio is presently 12.69%.

Analysts Set New Price Targets

CHE has been the topic of a number of research reports. Bank of America reduced their price target on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Royal Bank Of Canada reduced their target price on shares of Chemed from $589.00 to $572.00 and set an “outperform” rating on the stock in a research report on Monday. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, October 8th. Oppenheimer reduced their target price on Chemed from $650.00 to $580.00 and set an “outperform” rating for the company in a research note on Thursday, July 31st. Finally, Jefferies Financial Group upgraded Chemed from a “hold” rating to a “buy” rating and lifted their price objective for the company from $490.00 to $550.00 in a research note on Tuesday, September 2nd. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $574.25.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.